The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being similar to Roche's Perjeta. The court invalidated an earlier restraint order, noting no patent infringement by Zydus. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
